- Home
- DGLY vs GRI Comparison
DGLY vs GRI Comparison
Compare DGLY & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGLY
- GRI
- Stock Information
- Founded
- DGLY 2004
- GRI 2018
- Country
- DGLY United States
- GRI United States
- Employees
- DGLY N/A
- GRI N/A
- Industry
- DGLY Radio And Television Broadcasting And Communications Equipment
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- DGLY Technology
- GRI Health Care
- Exchange
- DGLY Nasdaq
- GRI Nasdaq
- Market Cap
- DGLY 3.9M
- GRI 3.4M
- IPO Year
- DGLY N/A
- GRI N/A
- Fundamental
- Price
- DGLY $1.79
- GRI $1.29
- Analyst Decision
- DGLY
- GRI Strong Buy
- Analyst Count
- DGLY 0
- GRI 2
- Target Price
- DGLY N/A
- GRI $22.00
- AVG Volume (30 Days)
- DGLY 95.3K
- GRI 256.9K
- Earning Date
- DGLY 08-22-2025
- GRI 08-18-2025
- Dividend Yield
- DGLY N/A
- GRI N/A
- EPS Growth
- DGLY N/A
- GRI N/A
- EPS
- DGLY N/A
- GRI N/A
- Revenue
- DGLY $18,596,715.00
- GRI N/A
- Revenue This Year
- DGLY N/A
- GRI N/A
- Revenue Next Year
- DGLY N/A
- GRI N/A
- P/E Ratio
- DGLY N/A
- GRI N/A
- Revenue Growth
- DGLY N/A
- GRI N/A
- 52 Week Low
- DGLY $1.73
- GRI $1.10
- 52 Week High
- DGLY $183.00
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- DGLY 27.54
- GRI 41.52
- Support Level
- DGLY $1.73
- GRI $1.15
- Resistance Level
- DGLY $2.03
- GRI $1.28
- Average True Range (ATR)
- DGLY 0.09
- GRI 0.13
- MACD
- DGLY 0.18
- GRI -0.06
- Stochastic Oscillator
- DGLY 27.24
- GRI 15.32
About DGLY Digital Ally Inc.
Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.